BOSTON, MA and SEOUL, South Korea, June 22 2026
Insilico Medicine and SK Biopharmaceuticals have announced a landmark artificial intelligence-powered drug discovery collaboration valued at more than $2.5 billion, marking one of the largest AI-driven partnerships in the neuroimmune therapeutics sector. Unveiled during the BIO International Convention 2026, the agreement aims to accelerate the discovery and development of innovative treatments targeting neuroimmune disorders, including neuroinflammatory, neurodegenerative, and rare neurological diseases. The strategic alliance combines Insilico Medicine’s advanced Pharma.AI platform with SK Biopharmaceuticals’ extensive expertise in central nervous system (CNS) drug development, creating a powerful framework to advance next-generation therapies for patients facing severe neurological conditions with limited treatment options.
AI-Powered Discovery Targets Unmet Neuroimmune Needs
Under the collaboration, Insilico Medicine will utilize its proprietary Pharma.AI platform to identify, design, and optimize novel therapeutic candidates across multiple neuroimmune disease programs. The platform integrates target validation, generative chemistry, and molecule optimization technologies, enabling rapid identification of promising drug candidates. Neuroimmune disorders remain among the most challenging areas in medicine due to complex disease mechanisms and historically low clinical success rates. By combining advanced AI capabilities with deep biological expertise, the companies aim to significantly reduce discovery timelines and improve the probability of clinical success.
SK Biopharmaceuticals will contribute its proven capabilities in development, regulatory strategy, and commercialization, guiding programs through late-stage clinical development and global market introduction. The collaboration reflects a growing industry trend toward leveraging artificial intelligence in pharmaceutical R&D to address high-risk therapeutic areas more efficiently and effectively.
Record-Breaking Financial Structure Strengthens Strategic Partnership
Advertisement
The agreement provides Insilico Medicine with eligibility for up to $18 million in upfront and near-term milestone payments, while the total potential value of the collaboration exceeds $2.5 billion, including development, regulatory, and commercial milestones, along with single-digit royalties on future net sales. The deal represents the largest potential-value partnership Insilico has secured with an Asia-Pacific partner to date, underscoring increasing confidence in AI-enabled drug discovery platforms.
SK Biopharmaceuticals President and CEO Donghoon Lee emphasized that the collaboration expands the company’s CNS portfolio beyond epilepsy, building upon the commercial success of XCOPRI® (cenobamate). Company leaders highlighted that the partnership is designed not only to deliver individual therapeutic programs but also to establish a scalable innovation model capable of supporting future target discovery initiatives across multiple neurological disease areas.
Accelerating the Future of AI-Driven Pharmaceutical Innovation
The partnership further strengthens Insilico Medicine’s position as a leader in AI-native biotechnology innovation. The company has demonstrated the ability to reduce traditional preclinical drug discovery timelines from approximately 2.5–4 years to just 12–18 months, while requiring substantially fewer synthesized and tested molecules. Since 2021, Insilico has nominated 31 preclinical candidates, with 13 receiving Investigational New Drug (IND) approval or clearance. Beyond drug discovery, the company continues to advance scientific AI through initiatives such as MMAI Gym, a benchmarking and training platform designed to enhance domain-specific scientific reasoning and accelerate progress toward pharmaceutical superintelligence.
By integrating Insilico’s AI-driven discovery engine with SK Biopharmaceuticals’ global clinical development and commercialization expertise, the alliance seeks to unlock breakthrough therapies spanning traditional small molecules and emerging treatment modalities. Industry observers view the collaboration as a significant milestone demonstrating how AI technologies are reshaping pharmaceutical innovation, improving research productivity, and creating new opportunities to address some of the world’s most complex neurological diseases.
Source: Insilico Medicine, SK Biopharmaceuticals press release
